Skip to Main Content

Author Details

Daniel E Johnson
University of California San Francisco
1985
126
47
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36658129Author Correction: Head and neck squamous cell carcinoma.Nat Rev Dis Primers2023
36857322Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.PLoS One2023
36693157Transcription Factors and Cancer: Approaches to Targeting.Cancer J2023
36402737The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Adv Biol Regul2023
35158773NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022
36131561Emerging tyrosine kinase inhibitors for head and neck cancer.Expert Opin Emerg Drugs2022
35929989STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.Clin Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
32883697CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.Mol Cancer Res2021
33614939Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield.Laryngoscope Investig Otolaryngol2021
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
34779417Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.J Clin Invest2021
34680342Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018.Cancers (Basel)2021
34591642A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.Science2021
34045293Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.Clin Cancer Res2021
34346116PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.Head Neck2021
34362880Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.Cell Death Dis2021
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
33203730Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.Mol Cancer Ther2021
31594701NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.Adv Biol Regul2020
33521321Targeting the JAK/STAT pathway in solid tumors.J Cancer Metastasis Treat2020
32061630Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.Biochim Biophys Acta Mol Cell Res2020
31914141Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.PLoS One2020
33243986Head and neck squamous cell carcinoma.Nat Rev Dis Primers2020
33206698STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors.PLoS One2020
30683736Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer.J Exp Med2019
31661135Gene targets of sulforaphane in head and neck squamous cell carcinoma.Mol Med Rep2019
31345392ATR inhibition sensitizes HPV<sup>-</sup> and HPV<sup>+</sup> head and neck squamous cell carcinoma to cisplatin.Oral Oncol2019
30753792Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.Expert Opin Investig Drugs2019
29066276Signaling by cell surface death receptors: Alterations in head and neck cancer.Adv Biol Regul2018
29891486STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.Mol Cancer Ther2018
29848966Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.Int J Mol Sci2018
30376740An update: emerging drugs to treat squamous cell carcinomas of the head and neck.Expert Opin Emerg Drugs2018
29616864A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.Leuk Lymphoma2018
29420101Leveraging Genomics for Head and Neck Cancer Treatment.J Dent Res2018
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
29405201Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Nat Rev Clin Oncol2018
29709262New Therapies in Head and Neck Cancer.Trends Cancer2018
29173752Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.Semin Radiat Oncol2018
27986750Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2017
28821544When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.Cancer Prev Res (Phila)2017
28866730EGFR-targeted therapies in the post-genomic era.Cancer Metastasis Rev2017
25982282Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Oncogene2016
27855189Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.PLoS One2016
27868025A sensible approach to targeting STAT3-mediated transcription.Ann Transl Med2016
27267892STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.Cancer Prev Res (Phila)2016
27339168Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.Cancer Prev Res (Phila)2016
24659480The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.Endocr Relat Cancer2015
25868717Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions.Oral Oncol2015
  • 1 - 50 of 126

Recommended Authors

Jianying Zhang
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 0
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 2
Bin Yan
The University of Hong Kong
Career Start Year 2003
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Jinbo Yang
School of Medicine and Pharmacy, Ocean University of China
Career Start Year 2003
Number of shared co-authors 0
Fan Yang
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 0
Erxi Wu
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Career Start Year 1997
Number of shared co-authors 1
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 0
Zhong Chen
National Institute on Deafness and Other Communication Disorders
Career Start Year 1995
Number of shared co-authors 1
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 2
Ute Fischer
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 0
Seiji Kondo
Fukuoka University
Career Start Year 1992
Number of shared co-authors 1
Aykut Uren
Georgetown University Medical Center
Career Start Year 1991
Number of shared co-authors 1
Todd VanArsdale
Oncology Research Unit, Inc.
Career Start Year 1991
Number of shared co-authors 2
Cun-Yu Wang
University of California, Los Angeles (university of california los angeles)
Career Start Year 1991
Number of shared co-authors 0
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 0
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 0
Lawrence H Boise
Winship Cancer Institute, Emory University
Career Start Year 1988
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 0
Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 3
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 4
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 1
Carter Van Waes
National Institute of Deafness and Other Communication Disorders
Career Start Year 1984
Number of shared co-authors 7
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 3
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 3
Donald L Durden
Atrium Health-Levine Cancer Institute
Career Start Year 1979
Number of shared co-authors 3
Stanley Lipkowitz
Center for Cancer Research, National Cancer Institute
Career Start Year 1978
Number of shared co-authors 0
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 1

Collaborators

Jennifer R Grandis
University of California san francisco
Co-authored papers 67
Hua Li
University of California san francisco
Co-authored papers 16
Julie E Bauman
George Washington University
Co-authored papers 13
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 12
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 12
Lin Wang
Co-authored papers 8
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 8
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 8
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 6
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 6
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 5
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 5
Max V Ranall
University of California San Francisco
Co-authored papers 5
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 4
Margaret Soucheray
J. David Gladstone Institutes
Co-authored papers 4
Patrick K Ha
University of California San Francisco
Co-authored papers 4
Mi-Ok Kim
University of California san francisco
Co-authored papers 4
Raja R Seethala
University of Pittsburgh Medical Center-Presbyterian
Co-authored papers 3
Simon C Watkins
Center for Molecular Imaging, University of Pittsburgh School of Medicine
Co-authored papers 3
Hyunseok Kang
Johns Hopkins University
Co-authored papers 3
Danielle L Swaney
J. David Gladstone Institutes
Co-authored papers 3
Patricia Kropf
Novant Health Cancer Institute - Elizabeth
Co-authored papers 3
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 3
Michelle A Ozbun
The University of New Mexico School of Medicine
Co-authored papers 3
Charles R Leemans
Location Vrije Universiteit Amsterdam
Co-authored papers 2
Michelle Lee
University of California at San Francisco
Co-authored papers 2
Scott R VandenBerg
University of California san francisco
Co-authored papers 2
Sichuan Xi
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Zhenghe Wang
Co-authored papers 2
Release 1.2